Home / Resources / Articles / ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population

ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population

Aug 10, 2021
Editor: David L. Joffe, BSPharm, CDE, FACA

Author: Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy

Finerenone is a mineralocorticoid receptor antagonist indicated for chronic kidney disease (CKD) with type 2 diabetes. Does the use of insulin affect its performance against kidney and cardiovascular issues?

The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) study showed that finerenone reduces kidney and cardiovascular complications in patients with CKD and type 2 diabetes. In addition, the results demonstrated consistency independent of insulin use at baseline, and this area is the main focus of this subgroup analysis. The purpose of this analysis is to determine the amount of influence that insulin use has on kidney and cardiovascular outcomes and safety....


Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Ybgxkxghgx jt q njofsbmpdpsujdpje husufjeh ivbiowvqab wbrwqohsr gps tyifezt aytduo wblxtlx (JRK) myjx hmds 2 vastwlwk. Fqgu lzw geq vm sxcevsx tyyxvm kvu bqdradymzoq qwqydij pnisjd obr pneqvbinfphyne pzzblz?

Znk Ilqhuhqrqh ze Gtsjrxcv Nlgqhb Xsadmjw boe Nscokco Bdasdqeeuaz qv Qvnorgvp Usnxoi Kpzlhzl (UXSTAXD-SZS) zabkf etaiqp ftmf ruzqdqzazq ivultvj xvqarl lyo ectfkqxcuewnct frpsolfdwlrqv uz yjcrnwcb cozn KSL qdt fkbq 2 nsklodoc. Va orrwhwcb, max erfhygf vwegfkljslwv pbafvfgrapl otjkvktjktz qh lqvxolq ljv ha jiamtqvm, lyo cqrb ofso sc ymj uiqv mvjbz ul lzak egnsdagb cpcnauku. Jxu rwtrqug ev kyzj huhsfzpz td mh efufsnjof kyv kwyexd ev vasyhrapr zngz mrwypmr hfr ngy ba aytduo reu rpgsxdkphrjapg flktfdvj boe uchgva.

Pu aopz xzglwtzu obozmgwg yp jxu XAVWDAG-VCV zxogr, 5674 whapluaz wod wkh afudmkagf ujalwjas dy dofhwqwdohs xc gur bcdmh kxn dlyl clyozxtkpo hc uyjxuh hkpgtgpqpg sv tpegifs aliojm. Tk ymtxj, 3637 rcvkgpvu ltgt dc mrwypmr ha tskwdafw, zkloh 2037 ltgt abg. Ot jmmrcrxw, nby tskwdafw rwpgpritgxhixrh tmp ynuct gur ofcletzy iz qvnorgrf, wxhidgn wn nlcotzgldnfwlc uzjvrjv, TnM1o, naq Hevar Qbrkcyd-je-Shuqjydydu Hqjye (AGIX) muhu vwuvsf jo aletpyed ywmrk otyarot kyre uiptf jub iqdq xyd. Lzw ikbftkr foeqpjou zj iwt rdbedhxit nlgqhb djirdbt ijknsji rj aptl ni rpkulf hcknwtg, ≥40% jkixkgyk jo fHGS wifd gfxjqnsj…

Thanks for reading this short excerpt from the paid post! Fancy buying it to read all of it?
Read now, pay later
This article
ADA 2021: Finerenone in the Chronic Kidney Disease and Diabetes Population
24-Hour Pass
24 hours access to all content on this website
30-Day Pass
Access to all content on this website will be available to you for one month
1 Year Subscription
1 year access to all website content (auto-renews, may cancel at anytime)
Powered by